Rosetta Genomics Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ROSGQ research report →
Companywww.rosettagenomics.com
Rosetta Genomics Ltd. operates as a genomic diagnostics company worldwide. The company's microRNA technologies based diagnostic tests include RosettaGX Cancer Origin for the identification of the primary site of metastatic cancer; mi-KIDNEY, a kidney tumor classification test for pathology samples; RosettaGX Reveal for the diagnosis of indeterminate thyroid fine-needle aspirate samples; and mi-LUNG diagnostic tests.
- CEO
- Douglas Sites
- IPO
- 2007
- Employees
- 86
- HQ
- Rehovot, IL
Price Chart
Valuation
- Market Cap
- $593
- P/E
- -0.00
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- 0.15
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 19.44%
- Op Margin
- -169.63%
- Net Margin
- -175.80%
- ROE
- -135.07%
- ROIC
- -189.08%
Growth & Income
- Revenue
- $9.23M · 11.68%
- Net Income
- $-16,233,000 · 6.41%
- EPS
- $-9.31 · 32.49%
- Op Income
- $-15,664,000
- FCF YoY
- 38.45%
Performance & Tape
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- 5.34
- Avg Volume
- 45
Get TickerSpark's AI analysis on ROSGQ
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our ROSGQ Coverage
We haven't published any research on ROSGQ yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ROSGQ Report →